{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.08","value":"13.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"}],"units":"Participants"}],"description":"The average idelalisib exposure was summarized.","dispersionType":"Standard Deviation","groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.","id":"OG000","title":"Idelalisib"}],"paramType":"MEAN","populationDescription":"Participants in the ITT Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Start of Treatment to End of Treatment (up to 81 months)","title":"Study Drug Exposure","type":"SECONDARY","unitOfMeasure":"months"}